WAVEMAN · COMPANY

PLX · Protalix Biotherapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

PLX

Name: Protalix BioTherapeutics, Inc. (PLX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Protalix BioTherapeutics, Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001006281

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-1.2%

XBRL, annual

NET MARGIN

-12.5%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

58 funds added or opened last quarter

below 52% of Pharma & Biotech

REVENUE

-1.2% year over year

below 59% of Pharma & Biotech

MARGIN

-12.5% net margin

more than 54% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

58 funds added or opened positions in the latest 13F quarter, of 104 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +57.9%

+57.9%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 58 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Protalix BioTherapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Bashan Dror

PRESIDENT AND CEO

BUY

2025-12-19

56,000.0

$101.4K

Bar-Shalev Amos

Director

SELL

2025-11-18

168.0

$314

Schwartz Aharon

Director

BUY

2025-06-10

129,000.0

$206.4K

Bashan Dror

PRESIDENT AND CEO

BUY

2023-10-19

16,129.0

$22.7K

Bashan Dror

PRESIDENT AND CEO

BUY

2023-10-19

48,387.0

$67.7K

7 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 2 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

4,046,650.0 sh

$9.4M

RENAISSANCE TECHNOLOGIES LLC

1,096,000.0 sh

$2.6M

STATE STREET CORP

983,582.0 sh

$2.3M

GEODE CAPITAL MANAGEMENT, LLC

979,995.0 sh

$2.3M

NORTHERN TRUST CORP

922,340.0 sh

$2.1M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Ultra-Small Company Market Fund

$390.6K POSITION · AS OF 2026-03-31

0.3%

GuideMark Small/Mid Cap Core Fund

$72.2K POSITION · AS OF 2026-03-31

0.1%

iShares Micro-Cap ETF

$399.1K POSITION · AS OF 2026-03-31

0.0%

WisdomTree U.S. SmallCap Fund

$173.8K POSITION · AS OF 2026-03-31

0.0%

Applied Finance IVS US SMID ETF

$4.2K POSITION · AS OF 2026-03-31

0.0%

1290 VT Micro Cap Portfolio

$28.3K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Mr. Bashan

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$1.2M

$1.5M

$604.5K

-4%

—

2024

$1.5M

$524.7K

$749.7K

+6%

—

2023

$2.7M

$3.2M

$902.7K

+30%

—

2022

$1.5M

$1.9M

$795.8K

-62%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$52.7M	$53.4M	$65.5M	$47.6M
OPERATING INCOME	$-5.5M	$3.9M	$10.5M	$-13.0M
NET INCOME	$-6.6M	$2.9M	$8.3M	$-14.9M
EPS (DILUTED)	-0.08	0.04	0.09	-0.31
OPERATING CASH FLOW	$-12.0M	$8.7M	$-1.3M	$-25.0M
CASH	$14.7M	$19.8M	$23.6M	$17.1M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE